This leads to improved skin appearance and enhanced immune function
From a safety standpoint, retatrutide's known adverse effect profile from phase II trials includes: Nausea, vomiting, and diarrhoea (gastrointestinal effects common to GLP-1 receptor agonists) Reduced appetite and potential nutritional deficiencies with prolonged use Elevated heart rate observed in some trial participants Pancreatitis and gallbladder disease , which are recognised class cautions for GLP-1based therapies and should be considered in the context of retatrutide, although retatrutide-specific data remain limited Thyroid C-cell changes , observed in rodent studies with GLP-1 receptor agonists
It does not interfere with systemic peptide protocols and can be incorporated alongside existing regimens without timing conflicts
Protecting the Mitochondria The mitochondria are the "power plants" of your cells
Exercise physiology: nutrition, energy, and human performance
Minerva Gastroenterologica e Dietologica